Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia

NCT02335268 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: N-Plate / romiplostim

Sponsor

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Collaborators

[object Object]